Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD Interactions of Amlodipine, Losartan, and Ezetimibe/Rosuvastatin in Healthy Males
NCT04081844Phase 1Completed
- Sponsor
- Hanmi Pharmaceutical
- Start
- May 2018
- Primary completion
- Jun 2018
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of amlodipine, losartan, ezetimibe and rosuvastatin in hypertension (HTN) and dyslipidemia, sponsored by Hanmi Pharmaceutical. Primary endpoints: Maximum Plasma Concentration at Steady State at Day 6 and Area Under the Curve over the Dosing Interval at Day 6. Started May 2018; status: completed.
02
Drugs
amlodipinelosartanezetimiberosuvastatin
03
Conditions
hypertension (HTN)dyslipidemia
Beyond the preview
Go deeper on NCT04081844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04081844.